Table 3.

NVP-AUY922 biodistribution: pharmacokinetic parameters

	Plasma	Tumor	Liver	Muscle	Heart	Lung
Cmax, μmol/L or nmol/g	14.08 ± 4.14	16.36 ± 3.84	30.94 ± 5.58	27.45 ± 6.64	36.86 ± 7.42	48.48 ± 10.11
T 1/2 elimination λ_z, hours	10.3	30	7.7	8	5.6	5.5
AUC(0-8), hours* μmol/L or hours*nmol/g	7.3	345	53	35	32	71

The concentration of NVP-AUY922 was determined by high-pressure liquid chromatography/tandem mass spectrometry after a single intravenous administration of 30 mg/kg to BT-474 tumor-bearing mice. The highest concentration (C_max), terminal half-life (T 1/2 _{elimination λ_z}), and exposure as determined by the area under the curve (AUC) were determined for each organ, plasma, and BT-474 xenograft (tumor).